Clovis Oncology, Inc. Expected to Post FY2018 Earnings of ($2.60) Per Share (CLVS)
Clovis Oncology, Inc. (NASDAQ:CLVS) – Stock analysts at Gabelli reduced their FY2018 EPS estimates for shares of Clovis Oncology in a research note issued on Thursday. Gabelli analyst J. He now expects that the biopharmaceutical company will earn ($2.60) per share for the year, down from their previous forecast of ($1.55). Gabelli has a “Buy” rating and a $125.00 price target on the stock. Gabelli also issued estimates for Clovis Oncology’s FY2019 earnings at $2.30 EPS.
Clovis Oncology (NASDAQ:CLVS) last announced its quarterly earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($1.29) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.27) by $0.02. The company had revenue of $14.62 million for the quarter, compared to analyst estimates of $13.07 million. Clovis Oncology’s revenue for the quarter was down 32.5% compared to the same quarter last year. During the same quarter last year, the company earned ($2.07) EPS.
CLVS has been the topic of a number of other reports. Morgan Stanley reaffirmed an “overweight” rating and issued a $79.00 price objective on shares of Clovis Oncology in a research note on Tuesday, May 2nd. ValuEngine raised Clovis Oncology from a “sell” rating to a “hold” rating in a research note on Friday, June 2nd. Cann reaffirmed a “hold” rating on shares of Clovis Oncology in a research note on Monday, July 31st. Credit Suisse Group reaffirmed an “outperform” rating and issued a $88.00 price objective on shares of Clovis Oncology in a research note on Friday, June 16th. Finally, Zacks Investment Research raised Clovis Oncology from a “hold” rating to a “buy” rating and set a $105.00 price objective on the stock in a research note on Wednesday, July 12th. Eight equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $81.59.
In other Clovis Oncology news, insider Gillian C. Ivers-Read sold 3,000 shares of the business’s stock in a transaction that occurred on Monday, May 15th. The stock was sold at an average price of $47.39, for a total value of $142,170.00. Following the transaction, the insider now directly owns 203,583 shares of the company’s stock, valued at $9,647,798.37. The sale was disclosed in a legal filing with the SEC, which is available through this link. Over the last three months, insiders sold 9,000 shares of company stock worth $602,310. Insiders own 17.40% of the company’s stock.
Several institutional investors have recently modified their holdings of the company. First Mercantile Trust Co. purchased a new position in shares of Clovis Oncology during the first quarter worth $115,000. Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of Clovis Oncology by 71.4% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,819 shares of the biopharmaceutical company’s stock worth $116,000 after buying an additional 758 shares during the last quarter. Advisors Asset Management Inc. raised its position in shares of Clovis Oncology by 160.7% in the second quarter. Advisors Asset Management Inc. now owns 1,895 shares of the biopharmaceutical company’s stock worth $177,000 after buying an additional 1,168 shares during the last quarter. Legato Capital Management LLC purchased a new position in shares of Clovis Oncology during the second quarter worth $220,000. Finally, Bank of Montreal Can raised its position in shares of Clovis Oncology by 284.9% in the second quarter. Bank of Montreal Can now owns 2,702 shares of the biopharmaceutical company’s stock worth $253,000 after buying an additional 2,000 shares during the last quarter. 90.67% of the stock is currently owned by institutional investors.
Clovis Oncology Company Profile
Clovis Oncology, Inc is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company’s product candidates include Rociletinib, Rubraca (Rucaparib) and Lucitanib. Rucaparib is an oral, small molecule poly adenosine diphosphate (ADP)-ribose polymerase (PARP) inhibitor of PARP1, PARP2 and PARP3 approved as a monotherapy for the treatment of patients with deleterious breast cancer (BRCA) (human genes associated with the repair of damaged deoxyribonucleic acid (DNA)) mutation (germline and/or somatic) associated advanced ovarian cancer.
Receive News & Ratings for Clovis Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.